Tenderwize
Zurück zur Suche

Open-house drug rebate agreements Berlin

AOK Nordost - Die Gesundheitskasse·Potsdam, Germany·Deadline Feb 21, 2027 · 180 days left·Open·Supplies
Structured notice only
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open-House-Arzneimittelrabattverträge gemäß § 130a Abs. 8c SGB V für die KV-Region Berlin

50/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Warum diese Bewertung?

Chance

50 / 100

Komplexität

30 / 100

Risikofaktoren

Open-House model may be superseded by regular discount contracts, leading to automatic termination of existing agreemen...

No guarantee of sales volume; contracts are non-exclusive and volume depends on prescribing behavior.

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 3 lots
  • Duration until Apr 2027
  • Conclusion of non-exclusive discount agreements for oncology medications under §130a Abs. 8c SGB V
  • Medications: Bevacizumab, Rituximab, Trastuzumab (parenteral preparations from finished drugs)
Vollständige Zusammenfassung anzeigen

Open-House procedure for non-exclusive discount agreements for oncology drugs (Bevacizumab, Rituximab, Trastuzumab) in Berlin. Eligible pharmaceutical companies can join at any time until 21.02.2027. Contracts run from 01.05.2026 to 30.04.2027. No estimated value provided. No competition-based award; all eligible participants are accepted.

Risiken

Open-House model may be superseded by regular discount contracts, leading to automatic termination of existing agreemen...

No guarantee of sales volume; contracts are non-exclusive and volume depends on prescribing behavior.

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Current commercial register excerpt (not older than 2 years) or power of attorney

Eligibility

  • Only pharmaceutical companies (pharmazeutische Unternehmen) are eligible

Administrative

  • Suitability proof via a signed self-declaration of reliability

Anforderungen können unvollständig sein.

Auftraggeber

Ort

Potsdam, DEU

Website

www.aok.de

Kennung

DE275390265

Tätigkeit

Health

Lose (3)

LOT-0001

Bevacizumab (ATC: L01FG01)

Non-exclusive discount agreement for Bevacizumab parenteral preparations for oncology use in Berlin. Open-House model, all eligible pharmaceutical companies can join.

SuppliesEU fundedElectronic submission

Ort

Germany

Dauer

Apr 2026 - Apr 2027

Kategorie

Pharmaceutical products

Frist

Deadline Feb 21, 2027

LOT-0002

Rituximab (ATC: L01FA01)

Non-exclusive discount agreement for Rituximab parenteral preparations for oncology use in Berlin. Open-House model, all eligible pharmaceutical companies can join.

SuppliesEU fundedElectronic submission

Ort

Germany

Dauer

Apr 2026 - Apr 2027

Kategorie

Pharmaceutical products

Frist

Deadline Feb 21, 2027

LOT-0003

Trastuzumab (ATC: L01FD01)

Non-exclusive discount agreement for Trastuzumab parenteral preparations for oncology use in Berlin. Open-House model, all eligible pharmaceutical companies can join.

SuppliesEU fundedElectronic submission

Ort

Germany

Dauer

Apr 2026 - Apr 2027

Kategorie

Pharmaceutical products

Frist

Deadline Feb 21, 2027

Vergabedetails

Veröffentlichungsdatum
11 Feb 2026
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
103459-2026

Dokumente (2)

Ähnliche Ausschreibungen